← Leaderboards
Jacqueline E. Payton
Washington University
$4,312,454
Attributed
$6,733,936
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $813.8K · FY2010–23$1M$750K$500K$250K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$6,733,936 · 4
By mechanism
R01$4,842,964 · 2
P01$1,890,972 · 2
Top collaborators
- Eugene M. Oltz10 shared
Most similar at Washington University
Same institution · by research overlap
- Daniel C Link$19,842,999
- Randall J Bateman$192,965,895
- Matthew J Walter$8,261,626
- John F Dipersio$33,235,840
- Christopher A Miller$5,424,298
Others in their field
Top investigators on “Genetic”
- Richard A Gibbs · Baylor College Of Medicine$577,061,667
- Eric S Lander · Whitehead Institute For Biomedical Res$560,806,052
- David R. Weir · University Of Michigan At Ann Arbor$322,225,557
- Richard K. Wilson · Washington University$316,685,275
- Lawrence Corey · Fred Hutchinson Cancer Center$312,182,347
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$302,429,647
Research focus
GeneticEpigenetic ProcessMalignant NeoplasmsResearch PersonnelCellsEpigenomeProgramsMolecularLinkGene ExpressionS LymphomaGenomeLaboratoriesGenomicsPeripheral BloodProteinsAttentionCollectionEquipment And Supply InventoriesQuality ControlEnvironmentBone MarrowDatabasesHigh Standard
Grant awards (21)
Core B - Specimen Database.$181,509
P01 · FY2023 · CA · contact PI
Core B - Specimen Database.$128,652
P01 · FY2022 · CA · contact PI
Core B - Specimen Database.$157,084
P01 · FY2021 · CA · contact PI
Core B - Specimen Database.$129,867
P01 · FY2020 · CA · contact PI
SEQUENCE-SPECIFIC CHROMATIN MODIFIERS; NOVEL PROTEIN THERAPEUTICS FOR B CELL LYMPHOMA$338,378
R01 · FY2019 · CA · contact PI
Core B - Specimen Database.$84,666
P01 · FY2019 · CA · contact PI
SEQUENCE-SPECIFIC CHROMATIN MODIFIERS; NOVEL PROTEIN THERAPEUTICS FOR B CELL LYMPHOMA$348,844
R01 · FY2018 · CA · contact PI
Specimen Acquisition, Genomic, Transcriptomic and Epigenetic Profilling$98,166
P01 · FY2018 · CA · contact PI
SEQUENCE-SPECIFIC CHROMATIN MODIFIERS; NOVEL PROTEIN THERAPEUTICS FOR B CELL LYMPHOMA$348,844
R01 · FY2017 · CA · contact PI
Specimen Acquisition, Genomic, Transcriptomic and Epigenetic Profilling$212,765
P01 · FY2017 · CA · contact PI
SEQUENCE-SPECIFIC CHROMATIN MODIFIERS; NOVEL PROTEIN THERAPEUTICS FOR B CELL LYMPHOMA$348,844
R01 · FY2016 · CA · contact PI
Specimen Acquisition, Genomic, Transcriptomic and Epigenetic Profilling$227,227
P01 · FY2016 · CA · contact PI
SEQUENCE-SPECIFIC CHROMATIN MODIFIERS; NOVEL PROTEIN THERAPEUTICS FOR B CELL LYMPHOMA$348,844
R01 · FY2015 · CA · contact PI
Specimen Acquisition, Genomic, Transcriptomic and Epigenetic Profilling$226,573
P01 · FY2015 · CA · contact PI
TARGETING EPIGENOMIC SIGNATURES IN NON-HODGKIN LYMPHOMA FOR NOVEL THERAPEUTICS$594,657
R01 · FY2014 · CA
Specimen Acquisition, Genomic, Transcriptomic and Epigenetic Profilling$219,154
P01 · FY2014 · CA · contact PI
TARGETING EPIGENOMIC SIGNATURES IN NON-HODGKIN LYMPHOMA FOR NOVEL THERAPEUTICS$585,023
R01 · FY2013 · CA
Specimen Acquisition, Genomic, Transcriptomic and Epigenetic Profilling$225,309
P01 · FY2013 · CA · contact PI
TARGETING EPIGENOMIC SIGNATURES IN NON-HODGKIN LYMPHOMA FOR NOVEL THERAPEUTICS$635,460
R01 · FY2012 · CA
TARGETING EPIGENOMIC SIGNATURES IN NON-HODGKIN LYMPHOMA FOR NOVEL THERAPEUTICS$638,948
R01 · FY2011 · CA
TARGETING EPIGENOMIC SIGNATURES IN NON-HODGKIN LYMPHOMA FOR NOVEL THERAPEUTICS$655,122
R01 · FY2010 · CA